Back to News
Market Impact: 0.2
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Source: GlobeNewswire
Healthcare & Biotech
A Phase 2 clinical trial will evaluate the efficacy and safety of an unspecified treatment in participants with surgically diagnosed endometriosis and moderate-to-severe endometriosis-associated pain. The report provides no efficacy data, safety results, enrollment figures, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
More News
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
- Australia to investigate if OpenAI hack of government health website broke the law
- How an OpenAI ‘agent’ hacked Australia’s Medicare and what that means
- OpenAI's agent hacked into an Australian government website
- Prime Medicine receives FDA clearance for AATD gene therapy